Clinical Trials
27 trialsNCT06312176 2026-05-22
MK-2870-010
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06841354 2026-05-22
TroFuse-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06952504 2026-05-22
TroFuse-033
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06966700 2026-05-22
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07216703 2026-05-22
TroFuse-036
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04380636 2026-05-15
MK-7339-012
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06623422 2026-05-15
INTerpath-009
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06989112 2026-05-06
DE-01
AstraZeneca
Phase 3 Recruiting
NCT05173987 2026-05-05
KEYNOTE-C93
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03740165 2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03517449 2026-03-19
MK-3475-775
Eisai Inc.
Phase 3 Completed
NCT04895358 2026-03-11
KEYNOTE-B49
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05116189 2026-03-09
KEYNOTE-B96
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT03635567 2026-02-04
KEYNOTE-826
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04949256 2025-12-15
MK-7902-014
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT05298423 2025-08-01
KEYVIBE-006
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04634877 2025-06-09
KEYNOTE-B21
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04956692 2024-12-03
MK-3475-A86
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT02819518 2024-11-27
KEYNOTE-355
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02775435 2024-10-08
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03875092 2024-10-01
KEYNOTE-407
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03850444 2023-09-18
Keynote 042
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03019588 2023-03-30
MK-3475-063
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT03933449 2023-03-29
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02564263 2023-03-13
KEYNOTE-181
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02256436 2021-09-20
MK-3475-045
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03348904 2019-06-13
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
Incyte Corporation
Phase 3 Terminated